Search

Your search keyword '"Beshiri, Michael L."' showing total 14 results
Start Over Author "Beshiri, Michael L." Search Limiters Full Text
14 results on '"Beshiri, Michael L."'

2. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

Author

Karzai, Fatima, VanderWeele, David, Madan, Ravi A., Owens, Helen, Cordes, Lisa M., Hankin, Amy, Couvillon, Anna, Nichols, Erin, Bilusic, Marijo, Beshiri, Michael L., Kelly, Kathleen, Krishnasamy, Venkatesh, Lee, Sunmin, Lee, Min-Jung, Yuno, Akira, Trepel, Jane B., Merino, Maria J., Dittamore, Ryan, Marté, Jennifer, Donahue, Renee N., Schlom, Jeffrey, Killian, Keith J., Meltzer, Paul S., Steinberg, Seth M., Gulley, James L., Lee, Jung-Min, and Dahut, William L.

Published
2018
Full Text
View/download PDF

3. High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer

Author

Jansson, Keith H., Tucker, John B., Stahl, Lauren E., Simmons, John K., Fuller, Caitlyn, Beshiri, Michael L., Agarwal, Supreet, Fang, Lei, Hynes, Paul G., Alilin, Aian Neil, Lake, Ross, Abbey, Yasmine C., Cawley, Jacob, Tice, Caitlin M., Yin, JuanJuan, McKnight, Crystal, Klummp-Thomas, Carleen, Zhang, Xiaohu, Guha, Rajarshi, Hoover, Shelley, Simpson, R. Mark, Nguyen, Holly M., Corey, Eva, Thomas, Craig J., Proia, David A., and Kelly, Kathleen

Published
2018
Full Text
View/download PDF

5. Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1

Author

Lin, Wenchu, Cao, Jian, Liu, Jiayun, Beshiri, Michael L., Fujiwara, Yuko, Francis, Joshua, Cherniack, Andrew D., Geisen, Christoph, Blair, Lauren P., Zou, Mike R., Shen, Xiaohua, Kawamori, Dan, Liu, Zongzhi, Grisanzio, Chiara, Watanabe, Hideo, Minamishima, Yoji Andrew, Zhang, Qing, Kulkarni, Rohit N., Signoretti, Sabina, Rodig, Scott J., Bronson, Roderick T., Orkin, Stuart H., Tuck, David P., Benevolenskaya, Elizaveta V., Meyerson, Matthew, Kaelin, William G., and Yan, Qin

Published
2011

6. Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor

Author

Adelaiye-Ogala, Remi, primary, Gryder, Berkley E., additional, Nguyen, Yen Thi Minh, additional, Alilin, Aian Neil, additional, Grayson, Adlai R., additional, Bajwa, Wardah, additional, Jansson, Keith H., additional, Beshiri, Michael L., additional, Agarwal, Supreet, additional, Rodriguez-Nieves, Jose Antonio, additional, Capaldo, Brian, additional, Kelly, Kathleen, additional, and VanderWeele, David J., additional

Published
2020
Full Text
View/download PDF

7. CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer

Author

Hwang, Justin H., primary, Seo, Ji-Heui, additional, Beshiri, Michael L., additional, Wankowicz, Stephanie, additional, Liu, David, additional, Cheung, Alexander, additional, Li, Ji, additional, Qiu, Xintao, additional, Hong, Andrew L., additional, Botta, Ginevra, additional, Golumb, Lior, additional, Richter, Camden, additional, So, Jonathan, additional, Sandoval, Gabriel J., additional, Giacomelli, Andrew O., additional, Ly, Seav Huong, additional, Han, Celine, additional, Dai, Chao, additional, Pakula, Hubert, additional, Sheahan, Anjali, additional, Piccioni, Federica, additional, Gjoerup, Ole, additional, Loda, Massimo, additional, Sowalsky, Adam G., additional, Ellis, Leigh, additional, Long, Henry, additional, Root, David E., additional, Kelly, Kathleen, additional, Van Allen, Eliezer M., additional, Freedman, Matthew L., additional, Choudhury, Atish D., additional, and Hahn, William C., additional

Published
2019
Full Text
View/download PDF

8. The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib

Author

Marzi, Laetitia, primary, Szabova, Ludmila, additional, Gordon, Melanie, additional, Weaver Ohler, Zoe, additional, Sharan, Shyam K., additional, Beshiri, Michael L., additional, Etemadi, Moudjib, additional, Murai, Junko, additional, Kelly, Kathleen, additional, and Pommier, Yves, additional

Published
2019
Full Text
View/download PDF

9. A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening

Author

Beshiri, Michael L., primary, Tice, Caitlin M., additional, Tran, Crystal, additional, Nguyen, Holly M., additional, Sowalsky, Adam G., additional, Agarwal, Supreet, additional, Jansson, Keith H., additional, Yang, Qi, additional, McGowen, Kerry M., additional, Yin, JuanJuan, additional, Alilin, Aian Neil, additional, Karzai, Fatima H., additional, Dahut, William L., additional, Corey, Eva, additional, and Kelly, Kathleen, additional

Published
2018
Full Text
View/download PDF

10. Abstract B051: PDX-derived and patient-derived prostate cancer organoids as a clinically relevant platform for translational research

Author

Beshiri, Michael L., primary, Tice, Caitlin M., additional, Tran, Crystal, additional, Nguyen, Holly M., additional, Sowalsky, Adam G., additional, Agarwal, Supreet, additional, Jansson, Keith H., additional, McGowen, Kerry, additional, Alilin, Aian Neil, additional, Yin, JuanJuan, additional, Karzai, Fatima H., additional, Dahut, William L., additional, Corey, Eva, additional, and Kelly, Kathleen, additional

Published
2018
Full Text
View/download PDF

11. Gambogic acid inhibits thioredoxin activity and induces ROS-mediated cell death in castration-resistant prostate cancer

Author

Pan, Hong, primary, Jansson, Keith H., additional, Beshiri, Michael L., additional, Yin, JuanJuan, additional, Fang, Lei, additional, Agarwal, Supreet, additional, Nguyen, Holly, additional, Corey, Eva, additional, Zhang, Ying, additional, Liu, Jie, additional, Fan, HuiTing, additional, Lin, HongSheng, additional, and Kelly, Kathleen, additional

Published
2017
Full Text
View/download PDF

13. Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1

Author

Harvard University--MIT Division of Health Sciences and Technology, Meyerson, Matthew L., Lin, Wenchu, Cao, Jian, Liu, Jiayun, Beshiri, Michael L., Fujiwara, Yuko, Francis, Joshua M., Cherniack, Andrew D., Geisen, Christoph, Blair, Lauren P., Zou, Mike R., Shen, Xiaohua, Liu, Zongzhi, Grisanzio, Chiara, Watanabe, Hideo, Minamishima, Yoji Andrew, Zhang, Qing, Kulkarni, Rohit N., Signoretti, Sabina, Rodig, Scott J., Bronson, Roderick T., Orkin, Stuart H., Tuck, David P., Benevolenskaya, Elizaveta V., Kawamori, Dan, Kaelin Jr., William G., Qin, Yan, Harvard University--MIT Division of Health Sciences and Technology, Meyerson, Matthew L., Lin, Wenchu, Cao, Jian, Liu, Jiayun, Beshiri, Michael L., Fujiwara, Yuko, Francis, Joshua M., Cherniack, Andrew D., Geisen, Christoph, Blair, Lauren P., Zou, Mike R., Shen, Xiaohua, Liu, Zongzhi, Grisanzio, Chiara, Watanabe, Hideo, Minamishima, Yoji Andrew, Zhang, Qing, Kulkarni, Rohit N., Signoretti, Sabina, Rodig, Scott J., Bronson, Roderick T., Orkin, Stuart H., Tuck, David P., Benevolenskaya, Elizaveta V., Kawamori, Dan, Kaelin Jr., William G., and Qin, Yan

Abstract

Aberrations in epigenetic processes, such as histone methylation, can cause cancer. Retinoblastoma binding protein 2 (RBP2; also called JARID1A or KDM5A) can demethylate tri- and dimethylated lysine 4 in histone H3, which are epigenetic marks for transcriptionally active chromatin, whereas the multiple endocrine neoplasia type 1 (MEN1) tumor suppressor promotes H3K4 methylation. Previous studies suggested that inhibition of RBP2 contributed to tumor suppression by the retinoblastoma protein (pRB). Here, we show that genetic ablation of Rbp2 decreases tumor formation and prolongs survival in Rb1+/− mice and Men1-defective mice. These studies link RBP2 histone demethylase activity to tumorigenesis and nominate RBP2 as a potential target for cancer therapy., National Institutes of Health (U.S.) (Grant CA138631), National Institutes of Health (U.S.) (Grant CA076120), National Institutes of Health (U.S.) (Grant CA16359), Raymond and Beverley Sackler Foundation (Fund for the Arts and Sciences), Caring for Carcinoid Foundation, V Foundation for Cancer Research (V Scholar Award), Howard Hughes Medical Institute (Investigator), Doris Duke Charitable Foundation, Breast Cancer Alliance, Alexander and Margaret Stewart Trust

Published
2012

14. Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1.

Author

Wenchu Lin, Jian Cao, Jiayun Lui, Beshiri, Michael L., Yuko Fujiwara, Francis, Joshua, Cherniack, Andrew D., Geisen, Christoph, Blair, Lauren P., Zou, Mike R., Xiaohua Shen, Kawamori, Dan, Zongzhi Liu, Grisanzio, Chiara, Watanabe, Hideo, Minamishima, Yoji Andrew, Qing Zhang, Kulkarni, Rohit N., Kulkarni, Sabina Signoretti!, and Scott J. Rodigh

Subjects
HISTONES, METHYLATION, CANCER, RETINOBLASTOMA, CARRIER proteins, LYSINE
Abstract

Aberrations in epigenetic processes, such as histone methylation, can cause cancer. Retinoblastoma binding protein 2 (RBP2; also called JARID1A or KDM5A) can demethylate tri- and dimethylated lysine 4 in histone H3, which are epigenetic marks for transcription- ally active chromatin, whereas the multiple endocrine neoplasia type 1 (MEN1) tumor suppressor promotes H3K4 methylation. Previous studies suggested that inhibition of RBP2 contributed to tumor suppression by the retinoblastoma protein (pRB). Here, we show that genetic ablation of Rbp2 decreases tumor formation and prolongs survival in Rb1+/- mice and Menl-defective mice. These studies link RBP2 histone demethylase activity to tumorigenesis and nominate RBP2 as a potential target for cancer therapy. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results